#1 Clinical Trials Search in Europe

Montelukast Sodium

Montelukast Sodium, also known by the brand name Singulair, is a medication that has been the subject of numerous clinical trials. These studies aim to evaluate its effectiveness and safety in treating various respiratory conditions, primarily asthma and allergic rhinitis. The trials explore different formulations, dosages, and patient populations to better understand how Montelukast Sodium can be used to improve patient outcomes.

Table of Contents

What is Montelukast Sodium?

Montelukast Sodium, also known by its brand name Singulair, is a medication used to treat various respiratory conditions[1]. It belongs to a class of drugs called leukotriene receptor antagonists, which work by blocking certain natural substances that may cause or worsen asthma and allergic rhinitis symptoms[2].

Conditions Treated by Montelukast

Montelukast is primarily used to treat:

  • Asthma: It helps prevent and control asthma symptoms in adults and children[1].
  • Allergic Rhinitis: This includes both seasonal allergies (hay fever) and year-round allergies[2].
  • Exercise-Induced Bronchoconstriction: It can help prevent breathing difficulties during physical activity[6].
  • Chronic Obstructive Pulmonary Disease (COPD): Some studies have explored its use in COPD patients[7].

How Montelukast Works

Montelukast works by blocking substances called leukotrienes. Leukotrienes are chemicals that the body releases when you breathe in an allergen (such as pollen). These chemicals cause swelling in the airways and tightening of the muscles around the airways, which can lead to asthma symptoms. By blocking leukotrienes, Montelukast helps to reduce these effects, making it easier to breathe[2].

Forms and Dosages

Montelukast comes in several forms:

  • Tablets: Usually 10mg for adults, taken once daily[1].
  • Chewable tablets: Available in 4mg and 5mg strengths for children[3].
  • Oral granules: 4mg packets for young children[3].

The dosage depends on the patient’s age, condition being treated, and severity of symptoms. Always follow your doctor’s instructions or the directions on the label[3].

Effectiveness of Montelukast

Studies have shown that Montelukast can be effective in managing asthma and allergic rhinitis symptoms. In asthma patients, it has been found to improve lung function, reduce the need for rescue inhalers, and decrease the frequency of asthma attacks[6].

For allergic rhinitis, Montelukast can help reduce symptoms such as sneezing, runny nose, and nasal congestion. It’s particularly useful for patients who have both asthma and allergies[6].

However, it’s important to note that the effectiveness can vary from person to person. Some studies have shown mixed results, especially in older adults with asthma or COPD[7].

Potential Side Effects

While Montelukast is generally well-tolerated, it can cause side effects in some people. Common side effects may include:

  • Headache
  • Stomach pain
  • Diarrhea
  • Fatigue
  • Fever
  • Stuffy nose
  • Cough[5]

In rare cases, more serious side effects such as mood changes, behavior changes, or suicidal thoughts have been reported. If you experience any unusual or severe side effects, contact your healthcare provider immediately[5].

Use in Special Populations

Montelukast has been studied in various populations:

  • Children: It’s approved for use in children as young as 12 months old for certain conditions. Special formulations (chewable tablets and oral granules) are available for young children[3].
  • Older Adults: Some studies have looked at its effectiveness in older adults with asthma or COPD, with mixed results[7].
  • Pregnant Women: Limited data is available on its use during pregnancy. Always consult with your doctor if you’re pregnant or planning to become pregnant.

Ongoing Research and Potential New Uses

Research on Montelukast continues, exploring its potential benefits in other conditions:

  • Neonatal Sepsis: A study is investigating whether Montelukast could help modulate the response to sepsis in preterm infants[8].
  • Post-COVID-19 Persistent Cough: Researchers are exploring whether Montelukast could help treat persistent cough in patients who have recovered from COVID-19[9].

These potential new uses are still in the research phase and are not currently approved treatments. Always consult with your healthcare provider about the most appropriate treatments for your condition.

Aspect Details
Drug Forms Tablets (10mg), Oral Granules (4mg)
Main Conditions Studied Asthma, Allergic Rhinitis, COPD, Airway Reactivity
Key Outcome Measures Lung function (FEV1), Asthma symptom scores, Quality of life, Bioequivalence
Special Populations Older adults (≥50 years), Preterm infants
Study Designs Randomized, Crossover, Placebo-controlled
Duration of Trials Ranging from single-dose to 10 days to 8 weeks
Safety Considerations Monitoring for side effects such as diarrhea, colic, vomiting, fever, cough

FAQ

  • What is Montelukast Sodium used for? Montelukast Sodium is primarily used to treat asthma and allergic rhinitis (hay fever). It works by blocking certain substances in the body that cause inflammation in the airways.
  • How is Montelukast Sodium administered in clinical trials? In the trials, Montelukast Sodium is administered in various forms, including tablets and oral granules. The dosage typically ranges from 4mg to 10mg, depending on the patient's age and weight.
  • What are some of the main outcomes measured in Montelukast Sodium trials? Common outcomes measured include lung function (such as forced expiratory volume), asthma symptom scores, quality of life, and in some cases, bioequivalence with other formulations.
  • Are there any special considerations for Montelukast Sodium use in older adults? Some trials specifically focus on older adults (50 years and above) to assess the efficacy and safety of Montelukast Sodium in this population, as they may have different responses or needs compared to younger patients.
  • What are some potential side effects of Montelukast Sodium observed in trials? While generally well-tolerated, some reported side effects in trials include diarrhea, colic, vomiting, fever, and cough. However, it's important to note that side effects can vary between individuals.

Ongoing Clinical Trials on Montelukast Sodium

  • Study on Montelukast for Slowing Parkinson’s Disease Progression in Patients with Mild to Moderate Symptoms

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

  • A study testing dust mite allergy extracts from Dermatophagoides pteronyssinus and Dermatophagoides farinae for patients with allergic rhinoconjunctivitis with or without controlled asthma

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Spain

  • Study on the Long-Term Safety of Isatuximab for Adults with Multiple Myeloma Benefiting from Isatuximab Therapy

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Finland France Greece Italy Spain +1

  • Study on Methotrexate, Dexamethasone, and Montelukast to Prevent Infusion Reactions in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Spain

  • Study of Isatuximab, Lenalidomide, and Dexamethasone for Patients with High-Risk Smoldering Multiple Myeloma

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Denmark France Germany Greece Hungary +5

  • Study on Teclistamab and Drug Combination for Newly Diagnosed Multiple Myeloma Patients

    Not recruiting

    1 1 1
    Investigated drugs:
    France

  • Study on Isatuximab, Carfilzomib, and Dexamethasone for Adults with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    1 1 1
    Investigated drugs:
    Czechia Greece Portugal

  • Study Comparing Subcutaneous and Intravenous Isatuximab with Pomalidomide and Dexamethasone for Adults with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Germany Greece Hungary Italy +4

Glossary

  • Bioequivalence: A term used to describe when two medications have the same active ingredient and produce the same effect in the body.
  • Forced Expiratory Volume (FEV1): The amount of air a person can forcefully exhale in one second, used to measure lung function.
  • Allergic Rhinitis: An allergic reaction that causes inflammation in the nasal passages, often referred to as hay fever.
  • Leukotriene: A substance produced by the body that can cause inflammation in the airways, which Montelukast Sodium helps to block.
  • Crossover Study: A type of clinical trial where participants receive different treatments in a specific order, allowing comparison of effects within the same group.
  • Area Under Curve (AUC): A measure used in pharmacology to describe the total drug exposure over time.
  • Asthma Control Questionnaire (ACQ): A standardized set of questions used to assess how well a patient's asthma is controlled.
  • Spirometry: A common test used to assess how well your lungs work by measuring how much air you inhale and exhale.

References

  1. https://clinicaltrials.gov/study/NCT01671722
  2. https://clinicaltrials.gov/study/NCT01671709
  3. https://clinicaltrials.gov/study/NCT01691469
  4. https://clinicaltrials.gov/study/NCT01691456
  5. https://clinicaltrials.gov/study/NCT02029313
  6. https://clinicaltrials.gov/study/NCT00545844
  7. https://clinicaltrials.gov/study/NCT00162864
  8. https://clinicaltrials.gov/study/NCT04474327
  9. https://clinicaltrials.gov/study/NCT05447039